In BC, it has been reported to play a role in drug response, cell proliferation, migration, and invasion (37, 38) through several targeted pathways, such as STAT5B, KRAS, BDNF/TrkB; nevertheless, MYB has not been explored as a potential target of miR-134. This evidence concerns the gene MYB and breast cancer.